This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dalbavancin Study Results To Be Presented In Three Posters At The 53rd Annual ICAAC Meeting

CHICAGO, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two Phase 3 clinical trials of the company's lead product candidate, dalbavancin, will be presented in two posters at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, September 10-13, 2013. The trials were conducted via a Special Protocol Assessment based on the FDA's Draft Guidance for Developing Drugs for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Dalbavancin is under investigation for the treatment of ABSSSI caused by susceptible Gram-positive microorganisms. These data will be used to support the company's anticipated submission of a New Drug Application to the U.S. Food and Drug Administration at the end of September 2013.

In addition, R.M. Alden Research Lab will present in vitro data regarding the activity of dalbavancin against isolates obtained from osteomyelitis infections. This research was supported by a grant from Durata Therapeutics.

The following posters will be presented:

Tuesday, September 10, 2013
12 p.m. - 2 p.m.
Title: DISCOVER 1: A Randomized, Double-blind Study of Dalbavancin (DAL) compared to Vancomycin (V) (with an option to switch to Linezolid (L)) in Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Authors: H. W. Boucher 1, M. Wilcox 2, G. H. Talbot 3, A. Das 4, S. Puttagunta 5, M. Dunne 5 ( 1Tufts Med. Ctr., Boston, MA,  2Leeds Teaching Hosp., Leeds, UNITED KINGDOM,  3Talbot Advisors, LLC, Anna Maria, FL,  4InClin, San Mateo, CA,  5Durata Therapeutics, Branford, CT)
Poster #: L-201
 
Tuesday, September 10, 2013 
12 p.m. – 2 p.m.
Title: DISCOVER 2: A Randomized, Double-Blind Study of Dalbavancin (DAL) compared to Vancomycin (V) (with an option to switch to Linezolid (L)) in Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Authors: M. Wilcox 1, H. W. Boucher 2, G. H. Talbot 3, A. F. Das 4, S. Puttagunta 5, M. Dunne 5 ( 1Leeds Teaching Hosp., Leeds, UNITED KINGDOM,  2Tufts Med. Ctr., Boston, MA,  3Talbot Advisors, LLC, Anna Maria, FL,  4InClin, San Mateo, CA,  5Durata Therapeutics, Branford, CT)
Poster #: L-202
 
Tuesday, September 10, 2013 
12 p.m. – 2 p.m.
Title: In Vitro Activity of Dalbavancin Against Consecutive Isolates of Staphylococcus Species Recovered from Osteomyelitis Infections
Authors: D. M. Citron, E. J. Goldstein (R.M. Alden Res. Lab., Culver City, CA)
Poster #: E-140

The abstracts are currently available on the ICAAC website at www.icaac.org and copies of the posters will be available following the ICAAC meeting at www.duratatherapeutics.com

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient's hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs